Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clinicians. 2022;72:7–33. https://doi.org/10.3322/caac.21708.

Article  Google Scholar 

Chen K, O’Brien J, McVey A, Jenjitranant P, Kelly BD, Kasivisvanathan V, et al. Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short? Nat Rev Urol. 2022;20(2):116-23. https://doi.org/10.1038/s41585-022-00669-z.

Article  PubMed  Google Scholar 

Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–43. https://doi.org/10.1038/nature11125.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162:454. https://doi.org/10.1016/j.cell.2015.06.053.

Article  CAS  PubMed  Google Scholar 

Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, et al. The emerging role of PARP inhibitors in prostate cancer. Expert Rev Anticancer Ther. 2020;20:715–26. https://doi.org/10.1080/14737140.2020.1797497.

Article  CAS  PubMed  Google Scholar 

Conteduca V, Mosca A, Brighi N, de Giorgi U, Rescigno P. New prognostic biomarkers in metastatic castration-resistant prostate cancer. Cells. 2021;10:193. https://doi.org/10.3390/cells10010193.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oncology (Cancer) / Hematologic Malignancies Approval Notifications. https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications. Accessed 31 Oct 2023.

Maiorano BA, Conteduca V, Catalano M, Antonuzzo L, Maiello E, De Giorgi U, Roviello G. Personalized medicine for metastatic prostate cancer: the paradigm of PARP inhibitors. Crit Rev Oncol Hematol. 2023;192:104157. https://doi.org/10.1016/j.critrevonc.2023.104157

Article  PubMed  Google Scholar 

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102. https://doi.org/10.1056/NEJMoa1911440.

Article  PubMed  Google Scholar 

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383:2345–57. https://doi.org/10.1056/NEJMoa2022485.

Article  CAS  PubMed  Google Scholar 

Lynparza | European Medicines Agency [Internet]. https://www.ema.europa.eu/en/medicines/human/EPAR/Lynparza. Accessed 31 Oct 2023.

Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26:2487–96. https://doi.org/10.1158/1078-0432.CCR-20-0394.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, on behalf of the TRITON2 investigators, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. JCO. 2020;38:3763–72. https://doi.org/10.1200/JCO.20.01035.

Article  CAS  Google Scholar 

Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Loredo E, Procopio G, et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). JCO. 2022;40:11–11. https://doi.org/10.1200/JCO.2022.40.6_suppl.011.

Article  Google Scholar 

Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9). https://doi.org/10.1056/EVIDoa2200043.

Article  PubMed  PubMed Central  Google Scholar 

Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, et al. TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC). JCO. 2021;39:TP5089. https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS5089.

Article  Google Scholar 

Azad A, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, et al. Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study. JCO. 2023;41:5053–5053. https://doi.org/10.1200/JCO.2023.41.16_suppl.5053.

Article  Google Scholar 

Wang C, Li J. Haematologic toxicities with PARP inhibitors in cancer patients: an up to date meta analysis of 29 randomized controlled trials. J Clin Pharm Ther. 2021;46:571–84. https://doi.org/10.1111/jcpt.13349.

Article  CAS  PubMed  Google Scholar 

Nindra U, Hong JH, Balakrishnar B, Pal A, Chua W. Review of toxicities of PARP inhibitors in metastatic castrate resistant prostate cancer. Clin Genitourin Cancer. 2023;21:183–93. https://doi.org/10.1016/j.clgc.2022.07.005.

Article  PubMed  Google Scholar 

Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2017;11:3009–17. https://doi.org/10.2147/DDDT.S147726.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Cochrane Bias Methods Group; Cochrane Statistical Methods Group, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

Article  PubMed  PubMed Central  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

Article  CAS  PubMed  Google Scholar 

Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.

Article  Google Scholar 

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. https://doi.org/10.1002/sim.1186.

Article  PubMed  Google Scholar 

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708. https://doi.org/10.1056/NEJMoa1506859.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162–74. https://doi.org/10.1016/S1470-2045(19)30684-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Bono JS, Mehra N, Higano CS, Saad F, Buttigliero C, Mata M, et al. TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). JCO. 2020;38:119–119. https://doi.org/10.1200/JCO.2020.38.6_suppl.119.

Article  Google Scholar 

Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara PN, et al. Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Ann Oncol. 2019;30:v884–5. https://doi.org/10.1093/annonc/mdz394.043.

Article  Google Scholar 

Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19:975–86. https://doi.org/10.1016/S1470-2045(18)30365-6.

Article  CAS  PubMed  Google Scholar 

Chi KN, Rathkopf DE, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. JCO. 2022;40:12–12. https://doi.org/10.1200/JCO.2022.40.6_suppl.012.

Article  Google Scholar 

Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, TRITON3 Investigators, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719–32. https://doi.org/10.1056/NEJMoa2214676.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, et al. PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol Cancer Res. 2019;17:409–19. https://doi.org/10.1158/1541-7786.MCR-18-0138.

Article  CAS  PubMed  Google Scholar 

LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15–28. https://doi.org/10.1016/S1470-2045(18)30786-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Kelley RK, Melisko ME, et al. A phase I study of carboplatin and talazoparib in patients with and without DNA repair mutations. J Clin Oncol. 2017;35(15_suppl):2527.

Article  Google Scholar 

Farrés J, Llacuna L, Martin-Caballero J, Martínez C, Lozano JJ, Ampurdanés C, et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ. 2015;22:1144–57. https://doi.org/10.1038/cdd.2014.202.